Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock ...
Eli Lilly and Company (NYSE:LLY) develops and markets human pharmaceuticals. In the fourth full quarter of 2024, EPS increased 102% to $4.88 on a reported basis and 114% to $5.32 on a non-GAAP basis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results